HOME >> MEDICINE >> NEWS
ENBREL (Etanercept) Patient And Physician Support Web Site Launched

Web Site Offers Important Information And Support Programs For People With Rheumatoid Arthritis And For Their Health Care Providers

SEATTLE, April 6, 1999 - In an effort to better educate patients and health care providers about ENBREL (etanercept), a breakthrough treatment for rheumatoid arthritis (RA), Immunex Corporation and Wyeth-Ayerst Pharmaceuticals have launched the ENBREL Web Site: www.enbrel.com. ENBREL is used to treat moderately to severely active rheumatoid arthritis in people who have not adequately responded to one or more disease-modifying anti-rheumatic drugs (DMARDs).

The comprehensive internet site explains how ENBREL works in the body, offers a question and answer section, provides an interactive quiz to help RA sufferers and their doctors determine if ENBREL may be right for them, and highlights several patients' personal experiences with ENBREL. Color photography and animation add to the graphic interest of the site.

Enbrel.com also offers two toll-free numbers to provide support to patients who are considering or are currently taking ENBREL. For questions about insurance coverage, patients can call the Reimbursement Support Line (1-800-282-7704) where they will be connected with an insurance specialist. To answer any noninsurance questions about ENBREL and RA in general, trained telephone counselors are available at 1-888-4ENBREL. A link to the Arthritis Foundation Web Site is also provided.

Approximately 2.1 million Americans suffer from rheumatoid arthritis, an autoimmune disease that can strike at any age and affects three times as many women as men. ENBREL is the first in a class of rheumatoid arthritis drugs known as biologic response modifiers (BRMs), a new approach to RA management and the first breakthrough treatment in many years for people with rheumatoid arthritis.

In medical studies, just over one third of people treated with ENBREL (etanercept) rep
'"/>

Contact: Tim Warner
warnert@immunex.com
206-470-4193
Immunex Corporation
6-Apr-1999


Page: 1 2

Related medicine news :

1. ENBREL (etanercept) long-term clinical trial data
2. ENBREL application for early, active rheumatoid arthritis filed with the U.S. Food and Drug Administration
3. Circulation publishes phase I study of ENBREL in patients with chronic heart failure
4. ENBREL (Etanercept) Receives FDA Approval For Treatment Of Juvenile Rheumatoid Arthritis
5. Positive Results Of Pivotal Phase III Trial With ENBREL In Patients With Early, Active Rheumatoid Arthritis
6. ENBREL Phase III Data Published In Annals Of Internal Medicine
7. Patients newly diagnosed with HIV are more likely to enter outpatient care with case management
8. Patient with drug-resistant form of HIV identified
9. Patient knows best when it comes to ulcerative colitis, U-M study finds
10. Patients with cancer have highly increased risk for blood clots
11. Patients with previous heart attacks may not benefit from pacemaker implant

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: ENBREL Etanercept Patient And Physician Support Web Site Launched

(Date:4/1/2015)... This year for Oral Cancer Awareness Month, Herald ... an Open House to offer complimentary oral cancer screenings on ... An appointment is required and can be secured by calling ... In addition, Herald Square Dental and The Denture Center are ... April at the reduced cost of $39 (regularly $78). Half ...
(Date:4/1/2015)... The panel session will look at the need for ... program that can grow in a privacy-friendly manner, thus ... line. This topic has taken on even greater relevance ... dongles aren’t as secure as the automobile industry thought ... Progressive’s Snapshot dongles contained very significant security flaws, which ...
(Date:4/1/2015)... Orlando, FL (PRWEB) April 01, 2015 ... dedicated to providing the latest information on the top ... attempt to set the Guinness World Records title for ... as part of the 1st annual Baby Bellies & ... at 10am, and the Guinness World Record will commence ...
(Date:4/1/2015)... 2015 BioPlus Specialty Pharmacy ... has released a new app to keep health care ... chronic hepatitis C virus (HCV) infection. This ‘HCV Treatment ... from the American Association for the Study of Liver ... new direct-acting oral medications to treat HCV have been ...
(Date:4/1/2015)... Dr. Daniel C. Stewart ... to discuss the benefits of the LANAP® treatment over ... periodontal disease. People who live in Howard County, and ... can now visit Dr. Stewart, a Maryland dentist, for ... the LANAP® protocol, which is a laser gum surgery ...
Breaking Medicine News(10 mins):Health News:Herald Square Dental Celebrates Oral Cancer Awareness Month 2Health News:TU-Automotive: Office of The Privacy Commissioner of Canada To Set Out Privacy Considerations Surrounding UBI Products 2Health News:TU-Automotive: Office of The Privacy Commissioner of Canada To Set Out Privacy Considerations Surrounding UBI Products 3Health News:Baby Bellies & Beyond Attempts To Break Guinness World Records For “Mommy Moments” Largest Gathering Of Pregnant Women April 19 Outside Florida Hotel & Conference Center 2Health News:Baby Bellies & Beyond Attempts To Break Guinness World Records For “Mommy Moments” Largest Gathering Of Pregnant Women April 19 Outside Florida Hotel & Conference Center 3Health News:BioPlus Specialty Pharmacy Releases ‘HCV Treatment Path’ App for Hepatitis C Providers 2Health News:Dr. Daniel C. Stewart Offers Columbia Area Residents an Informational Seminar in April About Less Invasive Gum Disease Treatment Now Available at Smile Savers Dentistry 2Health News:Dr. Daniel C. Stewart Offers Columbia Area Residents an Informational Seminar in April About Less Invasive Gum Disease Treatment Now Available at Smile Savers Dentistry 3
(Date:4/1/2015)... 2015 Trinity Biotech plc (Nasdaq: ... diagnostic products for the point-of-care and clinical laboratory ... its wholly-owned subsidiary (the "Issuer"), intends to offer, ... aggregate principal amount of Exchangeable Senior Notes due ... buyers pursuant to Rule 144A under the Securities ...
(Date:4/1/2015)... , April 1, 2015  Hologic, Inc. (NASDAQ: ... of the 2.00% Convertible Exchange Senior Notes due 2037 ... Wilmington Trust Company, the trustee, paying agent and conversion ... convert the notes.  This conversion right is subject to ... dated as of December 10, 2007, as supplemented by ...
(Date:4/1/2015)... and ASPEN, Colo. , April ... with the Chris Klug Foundation (CKF), is pleased to sponsor ... being accepted for the award, which will recognize two ... life, whether it is a career accomplishment, participation in ... life with family and loved ones. ...
Breaking Medicine Technology:Trinity Biotech plc Announces Proposed Offering of $100 Million of Exchangeable Senior Notes due 2045 2Trinity Biotech plc Announces Proposed Offering of $100 Million of Exchangeable Senior Notes due 2045 3Trinity Biotech plc Announces Proposed Offering of $100 Million of Exchangeable Senior Notes due 2045 4Hologic Delivers Notice that Holders of 2.00% Convertible Exchange Senior Notes Due 2037 are Eligible to Convert 2Astellas Teams Up with The Chris Klug Foundation on the Bounce Back Award to Recognize Extraordinary Transplant Recipients 2Astellas Teams Up with The Chris Klug Foundation on the Bounce Back Award to Recognize Extraordinary Transplant Recipients 3
Cached News: